首页> 外国专利> BONE MARROW-DERIVED HEMATOPOIETIC PROGENITOR CELLS AND ENDOTHELIAL PROGENITOR CELLS AS PROGNOSTIC INDICATORS FOR CANCER

BONE MARROW-DERIVED HEMATOPOIETIC PROGENITOR CELLS AND ENDOTHELIAL PROGENITOR CELLS AS PROGNOSTIC INDICATORS FOR CANCER

机译:骨髓来源的造血祖细胞和内皮祖细胞作为癌症的预后指标

摘要

Methods of determining cancer progression or cancer relapse in a subject at risk for cancer progression or cancer relapse, the methods comprising: obtaining a sample from said subject; measuring the level of VEGFR1+ hematopoietic progenitor cells (HPCs) and/or VEGFR2+ endothelial progenitor cells (EPCs) in said sample; and taking additional samples and conducting additional measurements of HPCs and/or EPCs at one or more later time points. From the measurements, it can be determined whether there is a surge in the level of HPCs and/or EPCs in at least one later measurement, relative to an earlier measurement. A surge in the level of HPCs and/or EPCs indicates increased risk of progression or relapse of said subject's cancer.
机译:在具有癌症进展或癌症复发风险的受试者中确定癌症进展或癌症复发的方法,所述方法包括:从所述受试者获得样品;测量所述样品中VEGFR1 +造血祖细胞(HPC)和/或VEGFR2 +内皮祖细胞(EPC)的水平;并在一个或多个以后的时间点进行额外的采样并进行HPC和/或EPC的额外测量。从这些测量中,可以确定相对于先前的测量,在至少一个后续的测量中,HPC和/或EPC的水平是否存在激增。 HPC和/或EPC水平的升高表明所述受试者的癌症发展或复发的风险增加。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号